Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02612701 · ClinicalTrials.gov registry record · NA
E-Cigarette Aerosol, Conventional Cigarette Smoke, and Myocardial Perfusion
A NA study, sponsored by Cedars-Sinai Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 20
- Enrollment target
NCT02612701: Clinical Trial NA study, sponsored by Cedars-Sinai Medical Center.
NCT02612701 is a NA study that was terminated before completion, run by Cedars-Sinai Medical Center. The registered enrollment target is 20 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02612701, a NA study, was terminated before completion, sponsored by Cedars-Sinai Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
Study Summary
E-cigarettes deliver nicotine by creating an aerosol of ultrafine particles. Many questions remain about the size and composition and especially about the potential toxicity of these particles. Thus, a key unanswered question-and the research question proposed-is whether e-cigarette aerosol triggers the same acute impairment in coronary microvessel function as does conventional cigarette smoke, which delivers a very well-defined exposure to fine particles and many fold greater exposure to toxic (combustion) products including volatile organic compounds (such as acrolein) that have been implicated in the pathogenesis of tobacco-related coronary disease. Because the effects of nicotine on the human coronary microcirculation remain incompletely defined-with multiple potential vasodilator and vasoconstrictor actions each of which may vary by dose-we will determine the comparative effects of conventional cigarette smoke against e-cigarette aerosol with no nicotine, with low-dose nicotine, and with high-dose nicotine.
Primary Outcome
Myocardial contrast echocardiography will be used to measure regional myocardial perfusion - microvascular flux rate
Interventions
- OTHER Cigarettes
- OTHER E-cigarettes (nicotine free e-liquid)
- OTHER E-cigarettes (low nicotine e-liquid)
- OTHER E-cigarettes (high nicotine e-liquid)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-10 |
| Est. Completion | 2020-10 |
| Phase | NA |
Why NCT02612701 stopped before completion
NCT02612701 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 4 interventions - of which Cigarettes is the first listed.
NCT02612701 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02612701 about?
NCT02612701 is a clinical study titled "E-Cigarette Aerosol, Conventional Cigarette Smoke, and Myocardial Perfusion". E-cigarettes deliver nicotine by creating an aerosol of ultrafine particles. Many questions remain about the size and composition and especially about the potential toxicity of these particles. Thus, a key unanswered question-and the research question proposed-is whether e-cigarette aerosol triggers...
What is the current status of trial NCT02612701?
This trial is currently terminated. It is a NA study. The enrollment target is 20 participants. The study started on 2015-10. Estimated completion is 2020-10.
What interventions are being tested in trial NCT02612701?
The interventions under investigation include: Cigarettes (OTHER), E-cigarettes (nicotine free e-liquid) (OTHER), E-cigarettes (low nicotine e-liquid) (OTHER), E-cigarettes (high nicotine e-liquid) (OTHER).
Who is sponsoring clinical trial NCT02612701?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02612701's enrollment target sits among peer trials
20 1768th of 2000 higher than 140 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia